Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

NCT02133846 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02133846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02133846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2014
Completion date
September 30, 2019
Enrollment
44 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

corticobasal degeneration (cbd), corticobasal syndrome (cbs), primary four repeat tauopathies (4rt), progressive supranuclear palsy (psp)